Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...
- Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th - VANCOUVER, Feb. 6, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...
- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...
View all news releases
Next Generation DDR Therapeutics – Q1 2018
View All Presentations
Event RSVP: http://events.constantcontact.com/register/event?llr=mlhnstzab&oeidk=a07ef2arrx7482b90e8
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts